Esophageal cancer future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Created page with "{{Esophageal cancer}} {{CMG}} ==Overview== ==References== {{reflist|2}} Category:Disease Category:Types of cancer Category:Gastroenterology [[Category:Oncology..." |
|||
| (7 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Esophageal cancer}} | {{Esophageal cancer}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{HM}} | ||
== | ==Future Therapies== | ||
*Advances in the treatment of esophageal cancer are focused on:<ref name="pmid19934295">{{cite journal |vauthors=Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS |title=Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria |journal=Clin. Cancer Res. |volume=15 |issue=23 |pages=7412–20 |year=2009 |pmid=19934295 |doi=10.1158/1078-0432.CCR-09-1624 |url=}}</ref> | |||
**Fusion FDG- PET scanning for accurate staging | |||
**Immunotherapy checkpoint inhibitor such as pembrolizumab (Keytruda) that targets the programmed cell death - 1 (PD-1) receptor on the lymphocytes. | |||
*Recent developments include the analyzation of NY-ESO-1 cancer-testis (CT) antigen expression in esophageal cancer.<ref name="pmid22205715">{{cite journal |vauthors=Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM |title=CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1 |journal=Cancer Res. |volume=72 |issue=4 |pages=887–96 |year=2012 |pmid=22205715 |pmc=3288235 |doi=10.1158/0008-5472.CAN-11-2637 |url=}}</ref> | |||
**The high expression frequency of NY-ESO-1 in esophageal cancer could mean the development of a vaccine. | |||
==References== | ==References== | ||
| Line 9: | Line 16: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Gynecology]] | |||
[[Category: | [[Category:Needs content]] | ||
[[Category: | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 17:35, 27 December 2017
|
Esophageal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Esophageal cancer future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Esophageal cancer future or investigational therapies |
|
FDA on Esophageal cancer future or investigational therapies |
|
CDC on Esophageal cancer future or investigational therapies |
|
Esophageal cancer future or investigational therapies in the news |
|
Blogs on Esophageal cancer future or investigational therapies |
|
Risk calculators and risk factors for Esophageal cancer future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Future Therapies
- Advances in the treatment of esophageal cancer are focused on:[1]
- Fusion FDG- PET scanning for accurate staging
- Immunotherapy checkpoint inhibitor such as pembrolizumab (Keytruda) that targets the programmed cell death - 1 (PD-1) receptor on the lymphocytes.
- Recent developments include the analyzation of NY-ESO-1 cancer-testis (CT) antigen expression in esophageal cancer.[2]
- The high expression frequency of NY-ESO-1 in esophageal cancer could mean the development of a vaccine.
References
- ↑ Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009). "Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria". Clin. Cancer Res. 15 (23): 7412–20. doi:10.1158/1078-0432.CCR-09-1624. PMID 19934295.
- ↑ Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM (2012). "CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1". Cancer Res. 72 (4): 887–96. doi:10.1158/0008-5472.CAN-11-2637. PMC 3288235. PMID 22205715.